Real-world data and clinical observations are expanding the playbook for bispecific and CAR-T–style therapies by showing how dosing schedules and step-up management may be adapted without immediate safety penalties. In multiple myeloma, an observational series reported high responses with early ciltacabtagene autoleucel, paired with deep minimal residual disease clearance after one to three prior therapies (0ce8e? see below for ID mapping). Separately, a correspondence on teclistamab and talquetamab described six patients who continued extended-interval therapy without repeating the standard step-up dosing after prolonged gaps, avoiding acute inflammatory toxicities despite prior high rates of cytokine release syndrome during initial step-up.
Get the Daily Brief